Abstract：
Regulatory T cells (Tregs) are crucial in regulating T-cell-mediated immune responses. Numerous studies have shown that dysfunction or decreased numbers of Tregs may be involved in inflammatory cardiovascular diseases (CVDs) such as atherosclerosis, hypertension, myocardial infarction, myocarditis, cardiomyopathy, valvular heart diseases, heart failure, and abdominal aortic aneurysm. Tregs can help to ameliorate CVDs by suppressing excessive inflammation through various mechanisms, including inhibition of T cells and B cells, inhibition of macrophage-induced inflammation, inhibition of dendritic cells and foam cell formation, and induction of anti-inflammatory macrophages. Enhancing or restoring the immunosuppressive activity of Tregs may thus serve as a fundamental immunotherapy to treat hypertension and CVDs. However, the precise molecular mechanisms underlying the Tregs-induced protection against hypertension and CVDs remain to be investigated. This review focuses on recent advances in our understanding of Tregs subsets and function in CVDs. In addition, we discuss promising strategies for using Tregs through various pharmacological approaches to treat hypertension and CVDs.
摘要：
调节性T细胞(Tregs)在调节T细胞介导的免疫应答中是至关重要的。大量研究表明，Tregs的功能障碍或数量减少可能与炎症性心血管疾病（CVDs）如动脉粥样硬化有关。高血压,心肌梗塞,心肌炎,心肌病,心脏瓣膜病,心力衰竭,和腹主动脉瘤.Tregs可以通过各种机制抑制过度炎症来帮助改善CVD，包括抑制T细胞和B细胞,抑制巨噬细胞诱导的炎症，抑制树突状细胞和泡沫细胞形成，和诱导抗炎巨噬细胞。因此,增强或恢复Tregs的免疫抑制活性可以作为治疗高血压和CVD的基本免疫疗法。然而,Tregs诱导的抗高血压和心血管疾病的确切分子机制仍有待研究.这篇综述的重点是我们对CVD中Tregs子集和功能的理解的最新进展。此外,我们讨论了通过各种药理学方法使用Tregs治疗高血压和CVD的有希望的策略.
